Human Molecular Genetics and Genomics — Important Advances and Exciting Possibilities
By Francis S. Collins, M.D., Ph.D., Jennifer A. Doudna, Ph.D., Eric S. Lander, Ph.D., and Charles N. Rotimi, Ph.D.,
The New England Journal of Medicine
| 01. 07. 2021
The breathtaking progress in molecular genetics that has occurred over the past five decades and the transition to genomic medicine would have been difficult to imagine in 1970, when the Institute of Medicine (IOM), now the National Academy of Medicine (NAM), was formed. The term “genomics” hadn’t yet been coined, the tools and technologies that are the foundation of modern biotechnology were in their infancy, and methods for sequencing even a few nucleotides were barely workable.1
The IOM’s early years coincided with paradigm-shifting discoveries related to DNA, as biologic research swiftly incorporated Boyer and Cohen’s recombinant method, Sanger’s DNA-sequencing work, and Mullis’s introduction of polymerase chain reaction (PCR) technology (see timeline). Yet even against this backdrop, the notion of a “big science” endeavor to sequence the human genome seemed radical.
In 1987, the New York Times Magazine characterized the Human Genome Project as the “biggest, costliest, most provocative biomedical research project in history.”2 But in the years between the project’s launch in 1990 and its completion in 2003, genomic technology advanced dramatically. DNA-sequencing throughput increased from 1000... see more
Related Articles
"Black-footed Ferret Kits" by USFWS Mountain Prairie
is licensed under CC BY 2.0
The New York Times published on February 18 an enthusiastic article about a black-footed ferret, hailing it as “the first of any native, endangered animal species in North America to be cloned.”
As we have been documenting for many years (see below), grand claims for animal cloning go back to the birth of the first cloned sheep, in 1996. The New York Times was so excited by...
By Matthew Hutson, The New Yorker | 02.15.2021
In computer science, the main outlets for peer-reviewed research are not journals but conferences, where accepted papers are presented in the form of talks or posters. In June, 2019, at a large artificial-intelligence conference in Long Beach, California, called Computer...
By Adam Feuerstein, STAT | 02.16.2021
Bluebird Bio said Tuesday that it has suspended clinical trials involving its gene therapy for sickle cell disease after receiving reports that two patients treated with the one-time therapy were diagnosed with cancer.
The trials were placed on “temporary suspension”...
By Jocelyn Kaiser, Science | 02.16.2021
A company has stopped its clinical studies of a promising gene therapy for the blood disorder sickle cell disease after two people who participated developed leukemia-like cancer. Bluebird bio is now investigating whether a virus it uses to deliver a...